Targeting the Atypical Chemokine Receptor 2 (ACKR2) improves the benefit of anti-PD-1 immunotherapy in melanoma
M. Z. Noman, M. Szpakowska, M. Xiao, K. Van Moer, M. Ollert, G. Berchem, A. Chevigne, B. Janji
This study shows that targeting ACKR2 enhances anti-PD-1 immunotherapy efficacy in melanoma by improving the tumor microenvironment and immune cell infiltration.
bioRxiv · Apr 2, 2024 · PreprintCancer Biology